top of page

Foveal in the press

Merck's drug failure deals further blow to Alzheimer's theory

David Crow, New York, 15 February 2017

 

 

Biotech turns £10k into £40k in five years: still time to buy?

Kyle Caldwell 12 Septemeber 2015

 

 

Drugs firms are increasing their dementia spending

Jill Martin 24 July 2015

 

 

Fresh fears of biotech bubble as Axovant soars on NYSE debut

David Crow & Nicole Bullock, New York, 11 June 2015

 

 

Bristol's Opdivo cuts risk of lung cancer death for some

Deena Beasly 29 May 2015

 

 

Biotech: Making sense of the science

David Crow 13 April 2015

 

 

Big Pharma turns to small biotechs for edge in cancer treatment

Andrew Ward 7 April 2015

 

 

New cancer drugs 'vastly overestimated', says contrarian analyst

Ben Hirschler 31 March 2015

 

 

bottom of page